H
Hugo Farne
Researcher at National Institutes of Health
Publications - 33
Citations - 1226
Hugo Farne is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Asthma & COPD. The author has an hindex of 14, co-authored 30 publications receiving 916 citations. Previous affiliations of Hugo Farne include Guy's and St Thomas' NHS Foundation Trust & Northwick Park Hospital.
Papers
More filters
Journal ArticleDOI
Anti‐IL5 therapies for asthma
TL;DR: To compare the effects of therapies targeting IL-5 signalling with placebo on exacerbations, health-related qualify of life (HRQoL) measures, and lung function in adults and children with chronic asthma, a first update of a previously published review in The Cochrane Library is published.
Journal ArticleDOI
The role of viral infections in exacerbations of chronic obstructive pulmonary disease and asthma.
Richard J. Hewitt,Hugo Farne,Andrew I. Ritchie,Emma Luke,Sebastian L. Johnston,Patrick Mallia +5 more
TL;DR: Current knowledge of virus-induced exacerbations of asthma and COPD is discussed with a particular focus on mechanisms, human studies, virus–bacteria interactions and therapeutic advances.
Journal ArticleDOI
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon.
Lydia J. Finney,Nicholas Glanville,Hugo Farne,Julia Aniscenko,Peter Fenwick,Samuel V. Kemp,Maria Belen Trujillo-Torralbo,Su Ling Loo,Maria Adelaide Calderazzo,Jadwiga A. Wedzicha,Patrick Mallia,Nathan W. Bartlett,Sebastian L. Johnston,Aran Singanayagam +13 more
TL;DR: ICS therapies in COPD reduce expression of the SARS-CoV-2 entry receptor ACE2, which may contribute to altered susceptibility to COVID-19 in patients with COPD.
Journal ArticleDOI
Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-agonist alone for chronic obstructive pulmonary disease.
Hugo Farne,Christopher J Cates +1 more
TL;DR: Treatment with tiotropium plus LABA resulted in a slightly larger improvement in mean health-related quality of life (St George's Respiratory Questionnaire) and there were no significant differences in the other primary outcomes (hospital admission or mortality).
Journal ArticleDOI
Ability of King's College Criteria and Model for End-Stage Liver Disease Scores to Predict Mortality of Patients With Acute Liver Failure: A Meta-analysis
TL;DR: Based on a meta-analysis of studies, the KCC more accurately predicts hospital mortality among patients with AALF, whereas MELD scores more accurately predict mortalityamong patients with NAALF.